Drug Trial Radar · NCT02922686
Penicillin for the Emergency Department Outpatient Treatment of CELLulitis
Last checked: Nov 19, 2026Latest source record: Oct 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
414
Planned (sponsor's estimate)
Start
Dec 2016
Primary completion
Dec 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- Royal College of Surgeons, IrelandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Health Research Board, Ireland
- First posted
- Oct 4, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of this study is to investigate the non-inferiority of oral flucloxacillin alone compared with a combination of oral flucloxacillin and phenoxymethylpenicillin for the emergency department directed outpatient treatment of cellulitis, wound infections and abscesses, recently renamed by the Food and Drug Administration (FDA) as acute bacterial skin and skin structure infections (ABSSSIs). Half of the trial participants will receive flucloxacillin and placebo in combination, and the remaining half will be treated will flucloxacillin and phenoxymethylpenicillin. In a secondary objective the trial aims to measure adherence and persistence of trial patients with outpatient antibiotic therapy. In addition a within-trial evaluation of the cost per quality adjusted life year (QALY) gained from the use of oral flucloxacillin compared with combination therapy from the perspective of the health-care payer (direct costs) the patient and government. Finally the study will externally validate the Extremity Soft Tissue Infection-score, a Health Related Quality of Life (HRQL) questionnaire designed to quantify the impact of cellulitis, wound infections and abscesses on patient HRQL in clinical trials.
Conditions
- Cellulitis
- Wound Infection
- Abscess
Interventions
FlucloxacillinDrug
One flucloxacillin capsule of 500mg strength taken four times daily for 7 days
PhenoxymethylpenicillinDrug
One capsule of phenoxymethylpenicillin of 500 mg strength taken four times daily for 7 days
Placebo (for phenoxymethylpenicillin)Drug
Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-determined clinical responseTime frame: Test Of Cure visit (Day 14-21 post randomization)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Department of Emergency Medicine, Connolly Hospital,
Blanchardstown, Dublin, Ireland
Department of Emergency Medicine, Mater Misericordiae University Hospital
Dublin, Dublin, Ireland
Beaumont Hospital,
Dublin, Dublin, Ireland
Department of Emergency Medicine, Mercy University Cork
Cork, Greenville Place, Ireland
Department of Emergency Medicine, Cork University Hospital
Cork, Wilton, Ireland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.